A. O. Siefker-radtke, A. B. Apolo, T. J. Bivalacqua, P. E. Spiess, and P. C. Black, Immunotherapy with checkpoint blockade in the treatment of urothelial carcinoma, J Urol, 2017.

J. Bellmunt, R. De-wit, D. J. Vaughn, Y. Fradet, J. L. Lee et al., Investigators K-. Pembrolizumab as second-line therapy for advanced urothelial carcinoma, N Engl J Med, vol.376, pp.1015-1041, 2017.

T. Powles, I. Duran, M. S. Van-der-heijden, Y. Loriot, N. J. Vogelzang et al., Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): A multicentre, open-label, Lancet, vol.391, pp.748-57, 2018.

G. Edgren, L. Liang, H. O. Adami, and E. T. Chang, Enigmatic sex disparities in cancer incidence, Eur J Epidemiol, vol.27, pp.187-96, 2012.
DOI : 10.1007/s10654-011-9647-5

M. T. Dorak and E. Karpuzoglu, Gender differences in cancer susceptibility: An inadequately addressed issue, Front Genet, vol.3, p.268, 2012.
DOI : 10.3389/fgene.2012.00268
URL : https://www.frontiersin.org/articles/10.3389/fgene.2012.00268/pdf

A. Clocchiatti, C. E. Zhang, Y. Dotto, and G. P. , Sexual dimorphism in cancer, Nat Rev Cancer, vol.16, pp.330-339, 2016.

P. Hartge, E. B. Harvey, W. M. Linehan, D. T. Silverman, J. W. Sullivan et al., Unexplained excess risk of bladder cancer in men, J Natl Cancer Inst, vol.82, pp.1636-1676, 1990.

A. P. Arnold, A general theory of sexual differentiation, J Neurosci Res, vol.95, pp.291-300, 2017.

M. J. Schoemaker, A. J. Swerdlow, C. D. Higgins, A. F. Wright, P. A. Jacobs et al., Cancer incidence in women with Turner syndrome in Great Britain: A national cohort study, Lancet Oncol, vol.9, pp.239-285, 2008.

J. Ji, B. Zoller, J. Sundquist, and K. Sundquist, Risk of solid tumors and hematological malignancy in persons with Turner and Klinefelter syndromes: A national cohort study, Int J Cancer, vol.139, pp.754-762, 2016.

H. Druckrey, R. Preussmann, S. Ivankovic, and D. Schmahl, Organotropic carcinogenic effects of 65 various N-nitrosocompounds on BD rats, Z Krebsforsch, vol.69, pp.103-201, 1967.

J. S. Bertram and A. W. Craig, Specific induction of bladder cancer in mice by butyl-(4-hydroxybutyl)-nitrosamine and the effects of hormonal modifications on the sex difference in response, Eur J Cancer, vol.8, pp.587-94, 1972.

S. Kaneko and X. Li, X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism, Sci Adv, vol.4, p.5598, 2018.

K. Shin, A. Lim, J. I. Odegaard, J. D. Honeycutt, S. Kawano et al., Cellular origin of bladder neoplasia and tissue dynamics of its progression to invasive carcinoma, Nat Cell Biol, vol.16, pp.469-78, 2014.

J. Van-batavia, T. Yamany, A. Molotkov, H. Dan, M. Mansukhani et al., Bladder cancers arise from distinct urothelial sub-populations, Nat Cell Biol, vol.16, pp.982-91, 2014.

D. Fantini, A. P. Glaser, K. J. Rimar, Y. Wang, M. Schipma et al., A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer, Oncogene, 2018.

Z. He, W. Kosinska, Z. L. Zhao, X. R. Wu, and J. B. Guttenplan, Tissue-specific mutagenesis by N-butyl-N-(4hydroxybutyl)nitrosamine as the basis for urothelial carcinogenesis, Mutat Res, vol.742, pp.92-97, 2012.

H. Miyamoto, Z. Yang, Y. T. Chen, H. Ishiguro, H. Uemura et al., Promotion of bladder cancer development and progression by androgen receptor signals, J Natl Cancer Inst, vol.99, pp.558-68, 2007.

J. W. Hsu, I. Hsu, D. Xu, H. Miyamoto, L. Liang et al., Decreased tumorigenesis and mortality from bladder cancer in mice lacking urothelial androgen receptor, Am J Pathol, vol.182, pp.1811-1831, 2013.

S. K. Pal and A. Hurria, Impact of age, sex, and comorbidity on cancer therapy and disease progression, J Clin Oncol, vol.28, pp.4086-93, 2010.

F. Conforti, L. Pala, V. Bagnardi, D. Pas, T. Martinetti et al., Cancer immunotherapy efficacy and patients' sex: A systematic review and meta-analysis, Lancet Oncol, vol.19, pp.737-783, 2018.
DOI : 10.1016/s1470-2045(18)30261-4

S. Singh, W. Parulekar, N. Murray, R. Feld, W. K. Evans et al., Influence of sex on toxicity and treatment outcome in small-cell lung cancer, J Clin Oncol, vol.23, pp.850-856, 2005.

J. R. Brahmer, S. E. Dahlberg, R. J. Gray, J. H. Schiller, M. C. Perry et al., Sex differences in outcome with bevacizumab therapy: Analysis of patients with advanced-stage non-small cell lung cancer treated with or without bevacizumab in combination with paclitaxel and carboplatin in the Eastern Cooperative Oncology Group Trial 4599, J Thorac Oncol, vol.6, pp.103-111, 2011.

S. Riihijarvi, M. Taskinen, M. Jerkeman, and S. Leppa, Male gender is an adverse prognostic factor in B-cell lymphoma patients treated with immunochemotherapy, Eur J Haematol, vol.86, pp.124-132, 2011.

A. Botticelli, C. E. Onesti, I. Zizzari, B. Cerbelli, P. Sciattella et al., The sexist behaviour of immune checkpoint inhibitors in cancer therapy?, Oncotarget, vol.8, pp.99336-99346, 2017.

Y. Wu, Q. Ju, K. Jia, J. Yu, H. Shi et al., Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors), Int J Cancer, 2018.

R. Noy and J. W. Pollard, Tumor-associated macrophages: From mechanisms to therapy, Immunity, vol.41, pp.49-61, 2014.

A. Sica, T. Schioppa, A. Mantovani, and P. Allavena, Tumourassociated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy, Eur J Cancer, vol.42, pp.717-744, 2006.

S. Nucera, D. Biziato, D. Palma, and M. , The interplay between macrophages and angiogenesis in development, tissue injury and regeneration, Int J Dev Biol, vol.55, pp.495-503, 2011.

B. Z. Qian, J. Li, H. Zhang, T. Kitamura, J. Zhang et al., CCL2 recruits inflammatory monocytes to facilitate breasttumour metastasis, Nature, vol.475, pp.222-227, 2011.

N. Linde, M. Casanova-acebes, M. S. Sosa, A. Mortha, A. Rahman et al., Macrophages orchestrate breast cancer early dissemination and metastasis, Nat Commun, vol.9, p.21, 2018.

A. Mantovani, S. Sozzani, M. Locati, P. Allavena, and A. Sica, Macrophage polarization: Tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes, Trends Immunol, vol.23, pp.549-55, 2002.

B. Z. Qian and J. W. Pollard, Macrophage diversity enhances tumor progression and metastasis, Cell, vol.141, pp.39-51, 2010.

F. Aljabery, H. Olsson, O. Gimm, S. Jahnson, and I. Shabo, M2macrophage infiltration and macrophage traits of tumor cells in urinary bladder cancer, 2017.

V. G. Martinez, C. Rubio, M. Martinez-fernandez, C. Segovia, F. Lopez-calderon et al., BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer, Clin Cancer Res, vol.23, pp.7388-7399, 2017.

M. Tervahartiala, P. Taimen, T. Mirtti, I. Koskinen, T. Ecke et al., Immunological tumor status may predict response to neoadjuvant chemotherapy and outcome after radical cystectomy in bladder cancer, Sci Rep, vol.7, p.12682, 2017.

R. Pichler, J. Fritz, C. Zavadil, G. Schafer, Z. Culig et al., Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer, Oncotarget, vol.7, pp.39916-39930, 2016.

M. Miyake, S. Hori, Y. Morizawa, Y. Tatsumi, Y. Nakai et al., CXCL1-mediated interaction of cancer cells with tumorassociated macrophages and cancer-associated fibroblasts promotes tumor progression in human bladder cancer, Neoplasia, vol.18, pp.636-646, 2016.

B. Wang, H. Liu, X. Dong, S. Wu, H. Zeng et al., High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder, Oncotarget, vol.6, pp.20204-20218, 2015.

G. Sjodahl, K. Lovgren, M. Lauss, G. Chebil, O. Patschan et al., Infiltration of CD3(+) and CD68(+) cells in bladder cancer is subtype specific and affects the outcome of patients with muscleinvasive tumors, Urol Oncol, vol.32, pp.791-798, 2014.

M. Miyake, Y. Tatsumi, D. Gotoh, S. Ohnishi, T. Owari et al., Regulatory T cells and tumorassociated macrophages in the tumor microenvironment in non-muscle invasive bladder cancer treated with intravesical bacille calmette-guerin: A long-term follow-up study of a japanese cohort, Int J Mol Sci, vol.18, 2017.

T. Hanada, M. Nakagawa, A. Emoto, T. Nomura, N. Nasu et al., Prognostic value of tumor-associated macrophage count in human bladder cancer, Int J Urol, vol.7, pp.263-272, 2000.

H. Takayama, K. Nishimura, A. Tsujimura, Y. Nakai, M. Nakayama et al., Increased infiltration of tumor associated macrophages is associated with poor prognosis of bladder carcinoma in situ after intravesical bacillus Calmette-Guerin instillation, J Urol, vol.181, pp.1894-900, 2009.

C. Ayari, H. Larue, H. Hovington, M. Decobert, F. Harel et al., Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guerin immunotherapy, Eur Urol, vol.55, pp.1386-95, 2009.

C. D. Mills, L. L. Lenz, and R. A. Harris, A breakthrough: Macrophage-directed cancer immunotherapy, Cancer Res, vol.76, pp.513-519, 2016.
DOI : 10.1158/0008-5472.can-15-1737
URL : http://cancerres.aacrjournals.org/content/76/3/513.full.pdf

C. A. Penn, K. Yang, H. Zong, J. Y. Lim, A. Cole et al., Therapeutic impact of nanoparticle therapy targeting tumorassociated macrophages, Mol Cancer Ther, vol.17, pp.96-106, 2018.

S. K. Sandhu, K. Papadopoulos, P. C. Fong, A. Patnaik, C. Messiou et al., A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors, Cancer Chemother Pharmacol, vol.71, pp.1041-50, 2013.

M. H. Falk and R. D. Issels, Hyperthermia in oncology, Int J Hyperthermia, vol.17, pp.1-18, 2001.

R. A. Owusu, M. R. Abern, and B. A. Inman, Hyperthermia as adjunct to intravesical chemotherapy for bladder cancer, Biomed Res Int, p.262313, 2013.

I. I. Coley and . Wb, Contribution to the knowledge of sarcoma, Ann Surg, vol.14, pp.199-220, 1891.

B. Hildebrandt, P. Wust, O. Ahlers, A. Dieing, G. Sreenivasa et al., The cellular and molecular basis of hyperthermia, Crit Rev Oncol Hematol, vol.43, pp.33-56, 2002.

P. Wust, B. Hildebrandt, G. Sreenivasa, B. Rau, J. Gellermann et al., Hyperthermia in combined treatment of cancer, Lancet Oncol, vol.3, pp.487-97, 2002.

B. Frey, E. M. Weiss, Y. Rubner, R. Wunderlich, O. J. Ott et al., Old and new facts about hyperthermia-induced modulations of the immune system, Int J Hyperthermia, vol.28, pp.528-570, 2012.

P. Schildkopf, O. J. Ott, B. Frey, M. Wadepohl, R. Sauer et al., Biological rationales and clinical applications of temperature controlled hyperthermiaimplications for multimodal cancer treatments, Curr Med Chem, vol.17, pp.3045-57, 2010.

H. Maeda, K. Tsukigawa, and J. Fang, A retrospective 30 years after discovery of the enhanced permeability and retention effect of solid tumors: Next-generation chemotherapeutics and photodynamic therapy-problems, solutions, and prospects, Microcirculation, vol.23, pp.173-82, 2016.

H. Nakamura, J. Fang, and H. Maeda, Development of nextgeneration macromolecular drugs based on the EPR effect: Challenges and pitfalls, Expert Opin Drug Deliv, vol.12, pp.53-64, 2015.

D. T. Fisher, T. D. Vardam, J. B. Muhitch, and S. S. Evans, Finetuning immune surveillance by fever-range thermal stress, Immunol Res, vol.46, pp.177-88, 2010.
DOI : 10.1007/s12026-009-8122-9
URL : http://europepmc.org/articles/pmc2831163?pdf=render

R. D. Issels, Hyperthermia adds to chemotherapy, Eur J Cancer, vol.44, pp.2546-54, 2008.
DOI : 10.1016/j.ejca.2008.07.038

S. S. Evans, E. A. Repasky, and D. T. Fisher, Fever and the thermal regulation of immunity: The immune system feels the heat, Nat Rev Immunol, vol.15, pp.335-384, 2015.

R. J. Lammers, J. A. Witjes, B. A. Inman, I. Leibovitch, M. Laufer et al., The role of a combined regimen with intravesical chemotherapy and hyperthermia in the management of non-muscle-invasive bladder cancer: A systematic review, Eur Urol, vol.60, pp.81-93, 2011.

P. R. Stauffer and G. C. Van-rhoon, Overview of bladder heating technology: Matching capabilities with clinical requirements, Int J Hyperthermia, vol.32, pp.407-423, 2016.

B. A. Inman, P. R. Stauffer, O. A. Craciunescu, P. F. Maccarini, M. W. Dewhirst et al., A pilot clinical trial of intravesical mitomycin-C and external deep pelvic hyperthermia for non-muscle-invasive bladder cancer, Int J Hyperthermia, vol.30, pp.171-176, 2014.

T. Juang, P. R. Stauffer, O. A. Craciunescu, P. F. Maccarini, Y. Yuan et al., Thermal dosimetry characteristics of deep regional heating of non-muscle invasive bladder cancer, Int J Hyperthermia, vol.30, pp.176-83, 2014.

Y. Yuan, K. S. Cheng, O. I. Craciunescu, P. R. Stauffer, P. F. Maccarini et al., Utility of treatment planning for thermochemotherapy treatment of nonmuscle invasive bladder carcinoma, Med Phys, vol.39, pp.1170-81, 2012.

E. D. Geijsen, T. M. De-reijke, C. C. Koning, Z. Vorde-sive, P. J. Vording et al., Combining mitomycin C and regional 70MHz hyperthermia in patients with nonmuscle invasive bladder cancer: A pilot study, J Urol, vol.194, pp.1202-1210, 2015.

T. J. Arends, O. Nativ, M. Maffezzini, O. De-cobelli, G. Canepa et al., Results of a randomised controlled trial comparing intravesical chemohyperthermia with mitomycin C versus bacillus calmette-guerin for adjuvant treatment of patients with intermediate-and high-risk non-muscleinvasive bladder cancer, Eur Urol, vol.69, pp.1046-52, 2016.

A. Sousa, B. A. Inman, I. Pineiro, V. Monserrat, A. Perez et al., A clinical trial of neoadjuvant hyperthermic intravesical chemotherapy (HIVEC) for treating intermediate and high-risk non-muscle invasive bladder cancer, Int J Hyperthermia, vol.30, pp.166-70, 2014.

G. Kong, G. Anyarambhatla, W. P. Petros, R. D. Braun, O. M. Colvin et al., Efficacy of liposomes and hyperthermia in a human tumor xenograft model: Importance of triggered drug release, Cancer Res, vol.60, pp.6950-6957, 2000.

M. L. Hauck, S. M. Larue, W. P. Petros, J. M. Poulson, D. Yu et al., Phase I trial of doxorubicin-containing low temperature sensitive liposomes in spontaneous canine tumors, Clin Cancer Res, vol.12, pp.4004-4014, 2006.

A. M. Ponce, Z. Vujaskovic, F. Yuan, D. Needham, and M. W. Dewhirst, Hyperthermia mediated liposomal drug delivery, Int J Hyperthermia, vol.22, pp.205-218, 2006.

A. S. Mikhail, A. H. Negussie, W. F. Pritchard, D. Haemmerich, D. Woods et al., Lyso-thermosensitive liposomal doxorubicin for treatment of bladder cancer, Int J Hyperthermia, vol.33, pp.733-740, 2017.

J. Fallon, R. Tighe, G. Kradjian, W. Guzman, A. Bernhardt et al., The immunocytokine NHS-IL12 as a potential cancer therapeutic, Oncotarget, vol.5, pp.1869-84, 2014.

A. J. Vandeveer, J. K. Fallon, R. Tighe, H. Sabzevari, J. Schlom et al., Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an AntiPD-L1 Immune Checkpoint Inhibitor, Cancer Immunol Res, vol.4, pp.452-62, 2016.

M. J. Brunda, L. Luistro, R. R. Warrier, R. B. Wright, B. R. Hubbard et al., Antitumor and antimetastatic activity of interleukin 12 against murine tumors, J Exp Med, vol.178, pp.1223-1253, 1993.

G. Trinchieri, Interleukin-12: A cytokine at the interface of inflammation and immunity, Adv Immunol, vol.70, pp.83-243, 1998.

J. P. Leonard, M. L. Sherman, G. L. Fisher, L. J. Buchanan, G. Larsen et al., Effects of single-dose interleukin12 exposure on interleukin-12-associated toxicity and interferon-gamma production, Blood, vol.90, pp.2541-2549, 1997.

J. W. Kim, C. R. Heery, M. Bilusic, N. K. Singh, R. A. Madan et al., First-in-human phase i trial of nhs-il12 in advanced solid tumors, Journal of Clinical Oncology, vol.30, 2012.

M. E. Keir, M. J. Butte, G. J. Freeman, and A. H. Sharpe, PD-1 and its ligands in tolerance and immunity, Annu Rev Immunol, vol.26, pp.677-704, 2008.

Y. Latchman, C. R. Wood, T. Chernova, D. Chaudhary, M. Borde et al., PD-L2 is a second ligand for PD-1 and inhibits T cell activation, Nat Immunol, vol.2, pp.261-269, 2001.

S. L. Topalian, F. S. Hodi, J. R. Brahmer, S. N. Gettinger, D. C. Smith et al., Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N Engl J Med, vol.366, pp.2443-54, 2012.

T. Powles, J. P. Eder, G. D. Fine, F. S. Braiteh, Y. Loriot et al., MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer, Nature, vol.515, pp.558-62, 2014.

J. M. Chemnitz, R. V. Parry, K. E. Nichols, C. H. June, and J. L. Riley, SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation, J Immunol, vol.173, pp.945-54, 2004.

H. Dong, S. E. Strome, D. R. Salomao, H. Tamura, F. Hirano et al., Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion, Nat Med, vol.8, pp.793-800, 2002.

Y. Iwai, M. Ishida, Y. Tanaka, T. Okazaki, T. Honjo et al., Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc Natl Acad Sci U S A, vol.99, pp.12293-12300, 2002.

R. V. Parry, J. M. Chemnitz, K. A. Frauwirth, A. R. Lanfranco, I. Braunstein et al., CTLA-4 and PD-1 receptors inhibit Tcell activation by distinct mechanisms, Mol Cell Biol, vol.25, pp.9543-53, 2005.
DOI : 10.1128/mcb.25.21.9543-9553.2005
URL : https://mcb.asm.org/content/25/21/9543.full.pdf

W. Tabayoyong and J. Gao, The emerging role of immunotherapy in advanced urothelial cancers, Curr Opin Oncol, 2018.

G. Sjodahl, M. Lauss, K. Lovgren, G. Chebil, S. Gudjonsson et al., A molecular taxonomy for urothelial carcinoma, Clin Cancer Res, vol.18, pp.3377-86, 2012.
DOI : 10.1158/1078-0432.ccr-12-0077-t
URL : http://clincancerres.aacrjournals.org/content/18/12/3377.full.pdf

, Cancer Genome Atlas Research N. Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, vol.507, pp.315-337, 2014.

W. Choi, B. Czerniak, A. Ochoa, X. Su, A. Siefker-radtke et al., Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer, Nat Rev Urol, vol.11, pp.400-410, 2014.

J. S. Damrauer, K. A. Hoadley, D. D. Chism, C. Fan, C. J. Tiganelli et al., Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology, Proc Natl Acad Sci U S A, vol.111, pp.3110-3115, 2014.

A. G. Robertson, J. Kim, H. Al-ahmadie, J. Bellmunt, G. Guo et al., Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell, vol.171, pp.540-556, 2017.

R. Ren, K. Tyryshkin, C. H. Graham, M. Koti, and D. R. Siemens, Comprehensive immune transcriptomic analysis in bladder cancer reveals subtype specific immune gene expression patterns of prognostic relevance, Oncotarget, vol.8, pp.70982-1001, 2017.

J. E. Rosenberg, J. Hoffman-censits, T. Powles, M. S. Van-der-heijden, A. V. Balar et al.,

J. Bajorin, D. Nickles, D. Bourgon, R. Frampton, G. M. Cui et al., Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial, Lancet, vol.387, pp.1909-1929, 2016.

P. Sharma, M. Retz, A. Siefker-radtke, A. Baron, A. Necchi et al., Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): A multicentre, single-arm, phase 2 trial, Lancet Oncol, vol.18, pp.312-334, 2017.

J. Kardos, S. Chai, L. E. Mose, S. R. Selitsky, B. Krishnan et al., Claudin-low bladder tumors are immune infiltrated and actively immune suppressed, JCI Insight, vol.1, p.85902, 2016.
DOI : 10.1172/jci.insight.85902
URL : http://insight.jci.org/articles/view/85902/files/pdf

R. Seiler, H. Ashab, N. Erho, B. Van-rhijn, B. Winters et al., Impact of molecular subtypes in muscle-invasive bladder cancer on predicting response and survival after neoadjuvant chemotherapy, Eur Urol, vol.72, pp.544-54, 2017.

W. Choi, S. Porten, S. Kim, D. Willis, E. R. Plimack et al., Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy, Cancer Cell, vol.25, pp.152-65, 2014.

D. J. Mcconkey, W. Choi, Y. Shen, I. L. Lee, S. Porten et al., A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with bevacizumab in urothelial cancer, Eur Urol, vol.69, pp.855-62, 2016.

G. Sjodahl, P. Eriksson, F. Liedberg, and M. Hoglund, Molecular classification of urothelial carcinoma: Global mRNA classification versus tumour-cell phenotype classification, J Pathol, vol.242, pp.113-138, 2017.

G. Sjodahl, Molecular subtype profiling of urothelial carcinoma using a subtype-specific immunohistochemistry panel, Methods Mol Biol, vol.1655, pp.53-64, 2018.